Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors

Mojun Zhu, Brian A. Costello, Jun Yin, Adam M. Pettinger, Jonathan R. Strosberg, Charles Erlichman, Timothy J. Hobday

Research output: Contribution to journalArticlepeer-review


Objectives: Systemic therapies for pancreatic neuroendocrine tumors (PNETs) are limited. The combination of bevacizumab and temsirolimus showed significant antitumor activity, but the single-agent activity of bevacizumab was unknown. We conducted a single-arm, phase II trial to evaluate the efficacy of bevacizumab in PNETs. Methods: Patients with progressive disease by the Response Evaluation Criteria in Solid Tumors version 1.1 within 7 months of enrollment were eligible for bevacizumab 10 mg/kg every 2 weeks. Adverse events were assessed according to the Common Terminology Criteria for Adverse Events version 3.0. The primary end point was response rate (RR). Results: Twenty-four patients were enrolled and followed up for a median duration of 36.1 months. Confirmed RR was 12.5%; 75.0% of patients had stable disease at 6 months. Median progression-free survival was 18.0 months; median overall survival was not reached. Common grade 3 adverse events were hypertension (45.8%) and proteinuria (8.3%). No grade 4 adverse events were observed. Conclusions: Bevacizumab demonstrated promising antitumor activity in progressive PNETs comparable to standard targeted therapy. Although this study failed to reject the null hypothesis (RR, 10%), bevacizumab seems a reasonable monotherapy and a potential component of combination therapies given clinical activity and low rates of adverse events.

Original languageEnglish (US)
Pages (from-to)1435-1439
Number of pages5
Issue number10
StatePublished - 2021


  • Bevacizumab
  • Neuroendocrine
  • Pancreatic
  • Trial

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology


Dive into the research topics of 'Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors'. Together they form a unique fingerprint.

Cite this